California-based Kite Pharma sponsored a CAR-T cell therapy, which is discerned to be the United States' initial licensed gene therapy.
A team of researchers at Harvard Medical School and Boston Children's Hospital reported back in 2015 that they were able to restore rudimentary hearing in genetically deaf mice using gene therapy.
Duke Health researchers have developed a gene therapy that could enhance or even replace the only FDA-approved treatment currently available to patients with a rare, life-threatening condition that cripples the muscles.
A US research has successfully used gene therapy in correcting congenital deafness in mice. The new technique might be available in five to ten years according to the scientists.
